monotherapy (prostaglandin analogues). A therapeutic of beta-blockers and prostaglandin analogues was detected.

The greatest use of ophthalmological preparations (2015–2017) corresponded with lubricants, tobramycin-dexamethasone, tobramycin, diclofenac and latanoprost.

Regarding the medication which required to be taken into account with ophthalmological diseases, these were:

1. Anticholinergic drugs which can interact in patients with acute angle-closure glaucoma: hyoscine, tolterodine, tricyclic antidepressant, typical antipsychotic, hydroxyzine. Topiramate can produce glaucoma.
2. Alpha-1 adrenergic blockers. The discontinuation (or cancellation or suspension) in cataract interventions needs to be evaluated, due to the risk of inter-operative flaccid iris syndrome.

Conclusion Collaboration with the ophthalmologists was found to be useful and guarantees continuing care and an efficient use of the resources, as well as the acquisition of knowledge.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Improvement of pharmacological treatments in nursing homes: medication review by consultant pharmacists ejhp.bmj.com/content/22/4/207

No conflict of interest.

4CPS-184 OFF-LABEL USES OF BEVACIZUMAB IN OPHTHALMOLOGY IN A MOROCCAN UNIVERSITY HOSPITAL

¹O El Hamdaoui*, ²H Elorch, ¹F Rahmaoui, ¹Y Bensouda, ¹Y Elalaoui. ¹Faculty of Medicine and Pharmacy- Mohammed V University- Rabat- Morocco-, Hospital Pharmacy- Specialty Hospital., Rabat, Morocco; ²Faculty of Medicine and Pharmacy- Mohammed V University- Rabat- Morocco-, Department of Ophthalmology. Specialty Hospital., Rabat, Morocco

10.1136/ejhp-pharm-2019-eahpconf.333

Background Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody. Its off-label use has increased in the management of a variety of ophthalmology diseases.

Purpose The aim of this study was to analyse the off-label use of bevacizumab, outside of oncology indications, in the department of ophthalmology, in the Specialty Hospital of Rabat.

Material and methods Retrospective observational study including all ophthalmology patients under bevacizumab treatment between January 2017 and August 2018. Collected data were demographic- and treatment-related, the data were gathered from the medical records and from the pharmacy software.

Results Eighty-five patients (68.5% females, average age 62.66 ± 13 years) received intravitreal administration of bevacizumab in hospital (100 mg/4 ml). The dose used was 2.5 mg (0.1 ml). All of the injections used were off-label.

Off-label indications identified were 65% (64/85) of diabetic macular oedema (DME), 20% (10/85) of age-related macular degeneration (AMD) and 15% (11/85) of macular oedema secondary to retinal vein occlusion (RVO). On average, 5 ± 1.53 injections were used to treat DME, 10 ± 2.15 injections for AMD and 7 ± 3.42 injections for RVO.

The course of the disease was assessed by optical coherence tomography examination, which showed a 75% improvement in patients treated for DME, 60% of patients with OVR and 40% of patients with AMD.

During the study period, 32 vials were used to treat 85 patients (786 injections), on average 25 injections per vial (37.5% of volume lost per vial). Each vial cost € 230. If the

corresponding number of vials had been used, the total cost would have been € 7360.

Cost per patient were € 46 (DME), € 92 (AMD) and € 65 (RVO). Cost per diseases were € 2944 (DME), € 920 (AMD) and € 708 (RVO).

Compared to Lucentis (ranibizumab), has a label use for these pathologies. The cost differences are significant at about € 6 per injection for Avastin and € 800 per injection for Lucentis.

Conclusion The off-label use of bevacizumab appears to be useful as a salvage treatment for ocular diseases. The high economic impact makes it necessary to rationalise bevacizumab prescription and to prepare a pre-filled syringe in the pharmacy to prevent loss of volume and to reduce the risk of infection.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-185 THE EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY IN THE MANAGEMENT OF GAUCHER DISEASE

¹H Attijoui, ²A Cheikh, ¹Z Aliat, ¹M Lazrak, ¹I Bennani, ³H Mefetah, ¹M Bouatia*. ¹Mohammed V University-Faculty of Medicine and Pharmacy of Rabat, Chis, Rabat, Morocco; ²Abulcasis University, Pharmacy, Rabat, Morocco; ³Paediatric Hospital, Pharmacy, Rabat, Morocco

10.1136/ejhp-pharm-2019-eahpconf.334

Background Gaucher disease is a rare genetic disorder, due to a deficiency of glucocerebrosidase activity. It is most often manifested by hepatosplenomegaly, haematological and biochemical disorder. First-line treatment is based on enzyme replacement therapy (ERT).

Purpose To evaluate the tolerance and effectiveness of ERT in children with type 1 Gaucher disease.

Material and methods We report the case of four patients with type 1 Gaucher disease treated with ERT (once every 15 days) at the neuro-metabolic diseases unit of our hospital. The evaluation was performed on the basis of primary effectiveness variables (haemoglobin concentration, platelet count, liver parameters) and the reporting of adverse events.

Results There were three girls and one boy, whose clinical signs were manifested by hepatosplenomegaly and haematological disorder in all patients.

Patient 1: 9-year-old girl, early diagnosis, 1 year of treatment with imiglucerase, 5 months of interruption and resumption of ERT.

Parameter	Before ERT	During ERT	% change of parameters
Haemoglobin (g/dl)	10.7	13	+21%
Platelets x109/l	95	195	+105%
AST	49	24	-51%
ALT	24	19	-20%

Patient 2: 17-year-old girl, 10 months of treatment with imiglucerase.

Parameter	Before ERT	During ERT	% change of parameters
Haemoglobin (g/dl)	8.5	10.6	+25%
Platelets x109/l	41	391	+800%
AST	22	19	-13%
ALT	6	6	0%